Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins

The rivalry between Eli Lilly and Novo Nordisk
extends beyond a buzzy class of weight loss and diabetes drugs called GLP-1s.

The two drugmakers are also competing to develop once-weekly insulin injections.

Those shots could provide a longer-lasting and more convenient option than daily insulin and other common treatments for managing diabetes.